These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26175713)

  • 1. Autosomal Dominant Alzheimer Disease: A Unique Resource to Study CSF Biomarker Changes in Preclinical AD.
    Schindler SE; Fagan AM
    Front Neurol; 2015; 6():142. PubMed ID: 26175713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequency of mutations in the presenilin and amyloid precursor protein genes in early-onset Alzheimer disease in Spain.
    Lleó A; Blesa R; Queralt R; Ezquerra M; Molinuevo JL; Peña-Casanova J; Rojo A; Oliva R
    Arch Neurol; 2002 Nov; 59(11):1759-63. PubMed ID: 12433263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age.
    Sutphen CL; Jasielec MS; Shah AR; Macy EM; Xiong C; Vlassenko AG; Benzinger TL; Stoops EE; Vanderstichele HM; Brix B; Darby HD; Vandijck ML; Ladenson JH; Morris JC; Holtzman DM; Fagan AM
    JAMA Neurol; 2015 Sep; 72(9):1029-42. PubMed ID: 26147946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testing the amyloid cascade hypothesis: Prevention trials in autosomal dominant Alzheimer disease.
    Levin J; Vöglein J; Quiroz YT; Bateman RJ; Ghisays V; Lopera F; McDade E; Reiman E; Tariot PN; Morris JC
    Alzheimers Dement; 2022 Dec; 18(12):2687-2698. PubMed ID: 35212149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early striatal amyloid deposition distinguishes Down syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition.
    Cohen AD; McDade E; Christian B; Price J; Mathis C; Klunk W; Handen BL
    Alzheimers Dement; 2018 Jun; 14(6):743-750. PubMed ID: 29477284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asymptomatic Carriers of Presenilin-1 E318G Variant Show no Cerebrospinal Fluid Biochemical Signs Suggestive of Alzheimer's disease in a Family with Late-onset Dementia.
    Artuso V; Benussi L; Ghidoni R; Moradi-Bachiller S; Fusco F; Curtolo S; Roiter I; Forloni G; Albani D
    Curr Alzheimer Res; 2019; 16(1):1-7. PubMed ID: 30381075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
    Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
    Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phenotypic Similarities Between Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease: A Single-Family Case-Control Study.
    Day GS; Musiek ES; Roe CM; Norton J; Goate AM; Cruchaga C; Cairns NJ; Morris JC
    JAMA Neurol; 2016 Sep; 73(9):1125-32. PubMed ID: 27454811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein.
    Maia LF; Kaeser SA; Reichwald J; Hruscha M; Martus P; Staufenbiel M; Jucker M
    Sci Transl Med; 2013 Jul; 5(194):194re2. PubMed ID: 23863834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of the Aβ42/40 ratio to the cerebrospinal fluid biomarker profile increases the predictive value for underlying Alzheimer's disease dementia in mild cognitive impairment.
    Baldeiras I; Santana I; Leitão MJ; Gens H; Pascoal R; Tábuas-Pereira M; Beato-Coelho J; Duro D; Almeida MR; Oliveira CR
    Alzheimers Res Ther; 2018 Mar; 10(1):33. PubMed ID: 29558986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autosomal-dominant Alzheimer's disease mutations at the same codon of amyloid precursor protein differentially alter Aβ production.
    Suárez-Calvet M; Belbin O; Pera M; Badiola N; Magrané J; Guardia-Laguarta C; Muñoz L; Colom-Cadena M; Clarimón J; Lleó A
    J Neurochem; 2014 Jan; 128(2):330-9. PubMed ID: 24117942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
    Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
    Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.
    Fagan AM; Roe CM; Xiong C; Mintun MA; Morris JC; Holtzman DM
    Arch Neurol; 2007 Mar; 64(3):343-9. PubMed ID: 17210801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.
    Lanoiselée HM; Nicolas G; Wallon D; Rovelet-Lecrux A; Lacour M; Rousseau S; Richard AC; Pasquier F; Rollin-Sillaire A; Martinaud O; Quillard-Muraine M; de la Sayette V; Boutoleau-Bretonniere C; Etcharry-Bouyx F; Chauviré V; Sarazin M; le Ber I; Epelbaum S; Jonveaux T; Rouaud O; Ceccaldi M; Félician O; Godefroy O; Formaglio M; Croisile B; Auriacombe S; Chamard L; Vincent JL; Sauvée M; Marelli-Tosi C; Gabelle A; Ozsancak C; Pariente J; Paquet C; Hannequin D; Campion D;
    PLoS Med; 2017 Mar; 14(3):e1002270. PubMed ID: 28350801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical cerebrospinal fluid and volumetric magnetic resonance imaging biomarkers in Swedish familial Alzheimer's disease.
    Thordardottir S; Ståhlbom AK; Ferreira D; Almkvist O; Westman E; Zetterberg H; Eriksdotter M; Blennow K; Graff C
    J Alzheimers Dis; 2015; 43(4):1393-402. PubMed ID: 25182737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.
    Fleisher AS; Chen K; Quiroz YT; Jakimovich LJ; Gutierrez Gomez M; Langois CM; Langbaum JB; Roontiva A; Thiyyagura P; Lee W; Ayutyanont N; Lopez L; Moreno S; Muñoz C; Tirado V; Acosta-Baena N; Fagan AM; Giraldo M; Garcia G; Huentelman MJ; Tariot PN; Lopera F; Reiman EM
    JAMA Neurol; 2015 Mar; 72(3):316-24. PubMed ID: 25580592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.